Lee Tien-Li 4
4 · Aardvark Therapeutics, Inc. · Filed Sep 12, 2025
Insider Transaction Report
Form 4
Lee Tien-Li
DirectorChief Executive Officer10% Owner
Transactions
- Purchase
Common Stock
2025-09-12$8.50/sh+5,000$42,516→ 1,533,384 total - Purchase
Common Stock
2025-09-11$7.82/sh+6,000$46,926→ 1,528,384 total - Purchase
Common Stock
2025-09-10$7.91/sh+9,000$71,213→ 1,522,384 total
Holdings
- 1,474,028(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.84 to $7.95 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.8135 to $7.825 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.4199 to $8.69 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.